Skip to main
ARVN
ARVN logo

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 27%
Buy 41%
Hold 32%
Sell 0%
Strong Sell 0%

Bulls say

Arvinas Inc. demonstrates a positive outlook driven by the recent VERITAC-2 trial results, which showed a statistically significant median progression-free survival (mPFS) benefit in patients with ESR1 mutations, bolstering its competitive position in the biopharmaceutical landscape. The combination therapy of vepdeg with CDK4/6 inhibitors is supported by previous promising data, indicating a potential for differentiation and competitiveness, particularly if the mPFS exceeds four months for ESR1 mutant patients. Additionally, the trial data confirm a safe profile for vepdeg, with no dose-limiting toxicities or severe adverse events, reinforcing investor confidence in the therapeutic's efficacy and safety.

Bears say

Arvinas Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily due to concerns regarding the limited benefit of its treatment candidates in certain patient populations, which could result in restrictive labeling and delayed timelines for meaningful clinical differentiation. Additionally, the anticipated clinical and commercial risks associated with various product candidates, such as vepdegestrant, ARV-102, and ARV-766, remain high, potentially impacting revenue estimates if these candidates fail to meet expectations. The lack of momentum for earlier line studies and uncertainty about the company's broader pipeline further exacerbate the potential for limited market opportunities against increasing competition.

Arvinas Inc (ARVN) has been analyzed by 22 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 41% recommend Buy, 32% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 22 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.